Medesis Pharma S.A.
Clinical-stage biotech developing treatments using its AONYS® drug delivery platform.
ALMDP | PA
Overview
Corporate Details
- ISIN(s):
- FR0010844464
- LEI:
- 969500C15M96P00UR648
- Country:
- France
- Address:
- AVENUE DU GOLF, 34670 BAILLARGUES
- Website:
- https://www.medesispharma.com/
- Sector:
- Manufacturing
Description
Medesis Pharma is a clinical-stage pharmaceutical biotechnology company focused on developing treatments for serious diseases using its proprietary AONYS® drug delivery platform. The AONYS® technology is a micro-emulsion designed for buccal (oral) administration, enabling the intracellular delivery of various therapeutic molecules, including metal ions, interfering RNAs, and peptides. A key feature of the platform is its ability to transport active ingredients across the blood-brain barrier, making it a promising approach for neurological disorders. The company's development pipeline addresses diseases with high unmet medical needs, including neurodegenerative conditions like Alzheimer's disease and therapies for individuals exposed to nuclear radiation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-01-29 18:00 |
MEDESIS PHARMA : Phase 2 clinical trial for the treatment of Alzheimer's diseas…
|
English | 562.7 KB | ||
| 2024-01-29 18:00 |
MEDESIS PHARMA : Étude clinique de phase 2 pour le traitement de la maladie d’A…
|
French | 645.9 KB | ||
| 2024-01-12 17:45 |
MEDESIS PHARMA : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S2 2023
|
French | 910.1 KB | ||
| 2024-01-12 17:45 |
MEDESIS PHARMA CONFIRME SON ÉLIGIBILITÉ AU DISPOSITIF PEA-PME
|
French | 234.1 KB | ||
| 2023-12-20 18:00 |
MEDESIS PHARMA : Apport en trésorerie
|
French | 163.0 KB | ||
| 2023-10-27 18:00 |
MEDESIS PHARMA : ACTIVITÉS & RÉSULTATS DU 1ER SEMESTRE 2023
|
French | 1.0 MB | ||
| 2023-10-27 18:00 |
MEDESIS PHARMA: 2023 FIRST-HALF BUSINESS AND EARNINGS
|
English | 935.2 KB | ||
| 2023-10-27 18:00 |
MEDESIS PHARMA : RAPPORT FINANCIER SEMESTRIELS 2023
|
French | 2.1 MB | ||
| 2023-10-23 18:00 |
MEDESIS PHARMA PARTICIPE AU 16ème CONGRÈS INTERNATIONAL « CLINICAL TRIALS ON AL…
|
French | 681.6 KB | ||
| 2023-10-23 18:00 |
MEDESIS PHARMA PARTICIPATES IN THE 16th INTERNATIONAL CONGRESS “CLINICAL TRIALS…
|
English | 520.4 KB | ||
| 2023-10-17 08:00 |
FIN DU RECRUTEMENT DES 68 PATIENTS DANS L’ÉTUDE CLINIQUE DE PHASE 2 DE MEDESIS …
|
French | 630.1 KB | ||
| 2023-10-17 08:00 |
END OF ENROLLEMENT OF THE 68 PATIENTS IN MEDESIS PHARMA PHASE 2 CLINICAL STUDY …
|
English | 621.7 KB | ||
| 2023-10-13 08:45 |
MEDESIS PHARMA : AUGMENTATION DES MOYENS ALLOUÉS AU CONTRAT DE LIQUIDITÉ CONCL…
|
French | 248.2 KB | ||
| 2023-10-11 18:00 |
MEDESIS PHARMA: PUBLICATION OF A SCIENTIFIC ARTICLE IN THE JOURNAL OF ALZHEIMER…
|
English | 452.1 KB | ||
| 2023-10-11 18:00 |
MEDESIS PHARMA : PUBLICATION D’UN ARTICLE SCIENTIFIQUE DANS LE JOURNAL OF ALZHE…
|
French | 488.4 KB |
Automate Your Workflow. Get a real-time feed of all Medesis Pharma S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Medesis Pharma S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Medesis Pharma S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-16 | N/A | Other | Sell | 1,000 | 1,170.00 EUR |
| 2024-01-18 | N/A | Other | Sell | 800 | 669.60 EUR |
| 2023-07-21 | N/A | Other | Sell | 1,000 | 1,400.00 EUR |
| 2023-07-04 | N/A | Other | Sell | 5,000 | 7,100.00 EUR |
| 2023-05-23 | N/A | Other | Sell | 3,140 | 6,908.00 EUR |
Peer Companies
